#原研药老干部破防了。家里长辈很多都有慢性病，长期吃药。现在最坏的情况可能是走正规渠道，自费也买不到。有靠谱原研药、进口药走私渠道的朋友欢迎私聊我。国产药上市流程一言难尽，而且哪怕国产药再好，我也会让家里人至少观望五到十年再吃。推友有啥招，做了哪些应对措施，求分享。 https://t.co/90EbaNjFIT ...

Group 1 - The new hypertension treatment drug, Xinchaotuo® (Sacubitril/Alesartan Calcium Tablets), has been launched online by JD Health and is the first original ARNI (Angiotensin Receptor Neprilysin Inhibitor) antihypertensive drug developed in China, offering superior and safer blood pressure control [2] - Xinchaotuo® is the first ARNI drug developed in China and the second ARNI co-crystal drug globally, featuring a design that synchronizes the peak effects of its active metabolite, Sacubitril, and Alesartan, thereby extending the half-life of Alesartan and improving blood pressure control [2] - ARNI drugs not only provide effective blood pressure reduction but also offer heart and kidney protection, making them particularly suitable for patients with hypertension combined with heart failure or chronic kidney disease [2] Group 2 - Xinli Tai Pharmaceutical has strategically focused on the hypertension treatment area, developing a complete family of original Alesartan antihypertensive drugs, including single-agent and combination formulations [3] - JD Health aims to leverage its capabilities to help Xinchaotuo® reach a broader patient base, enhancing the treatment level for hypertension in China through this collaboration [3] - JD Health has been recognized as the "first station for the online launch of new specialty drugs," continuously expanding its value effect and providing innovative drug access to a wide range of patients [3]